Solitary plasmacytomas

Outcome and prognostic factors after definitive radiation therapy

Valerie Reed, Jatin Shah, L. Jeffery Medeiros, Chul S Ha, Ali Mazloom, Donna M. Weber, Isidora Y. Arzu, Robert Z. Orlowski, Sheeba K. Thomas, Ferial Shihadeh, Raymond Alexanian, Bouthaina S. Dabaja

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

BACKGROUND: The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: The authors retrospectively reviewed 84 patients with SP who were diagnosed and treated at The University of Texas MD Anderson Cancer Center during 1988 to 2008. The impact of tumor anatomic site, tumor size, and the presence of serum and urinary paraprotein at diagnosis was assessed on local control, survival, and the risk of developing multiple myeloma (MM). RESULTS: Fifty-nine patients (70%) had bone SP, and 25 patients (30%) had extramedullary SP. Serum paraprotein was present in 39 patients (46%). The median radiation dose was 45 grays (Gy) (range, 36-53.4 Gy). Local control was achieved in 77 patients (92%). Neither radiation dose nor tumor size predicted local control. The 5-year rate of progression to MM was 47% and was higher for patients with bone SP (56% vs 30% for extramedullary SP; P =.021), and patients who had serum paraprotein detected at diagnosis (60% vs 39%; P =.016). On univariate analysis, patients aged <60 years and men had higher rates of progression to MM, although the differences were not significant (P =.048 and P =.29, respectively). Multivariate analysis revealed that bone location and serum protein at diagnosis were associated statistically with progression to MM. The 5-year overall survival rate for the entire patient cohort was 78%, and no difference was observed between patients who had bone SP versus extramedullary SP (76% vs 85%, respectively; P =.274). CONCLUSIONS: The current results indicated that definitive radiation therapy for SP can provide excellent local control. Progression to MM remains the main problem and is more common among patients with bone SP and those who have serum paraprotein detected at diagnosis.

Original languageEnglish (US)
Pages (from-to)4468-4474
Number of pages7
JournalCancer
Volume117
Issue number19
DOIs
StatePublished - Oct 1 2011

Fingerprint

Plasmacytoma
Radiotherapy
Paraproteins
Multiple Myeloma
Bone and Bones
Serum
Neoplasms
Radiation
Blood Proteins
Multivariate Analysis
Survival Rate

Keywords

  • Bence-Jones
  • multiple myeloma
  • paraprotein
  • plasmacytoma
  • radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reed, V., Shah, J., Medeiros, L. J., Ha, C. S., Mazloom, A., Weber, D. M., ... Dabaja, B. S. (2011). Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer, 117(19), 4468-4474. https://doi.org/10.1002/cncr.26031

Solitary plasmacytomas : Outcome and prognostic factors after definitive radiation therapy. / Reed, Valerie; Shah, Jatin; Medeiros, L. Jeffery; Ha, Chul S; Mazloom, Ali; Weber, Donna M.; Arzu, Isidora Y.; Orlowski, Robert Z.; Thomas, Sheeba K.; Shihadeh, Ferial; Alexanian, Raymond; Dabaja, Bouthaina S.

In: Cancer, Vol. 117, No. 19, 01.10.2011, p. 4468-4474.

Research output: Contribution to journalArticle

Reed, V, Shah, J, Medeiros, LJ, Ha, CS, Mazloom, A, Weber, DM, Arzu, IY, Orlowski, RZ, Thomas, SK, Shihadeh, F, Alexanian, R & Dabaja, BS 2011, 'Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy', Cancer, vol. 117, no. 19, pp. 4468-4474. https://doi.org/10.1002/cncr.26031
Reed, Valerie ; Shah, Jatin ; Medeiros, L. Jeffery ; Ha, Chul S ; Mazloom, Ali ; Weber, Donna M. ; Arzu, Isidora Y. ; Orlowski, Robert Z. ; Thomas, Sheeba K. ; Shihadeh, Ferial ; Alexanian, Raymond ; Dabaja, Bouthaina S. / Solitary plasmacytomas : Outcome and prognostic factors after definitive radiation therapy. In: Cancer. 2011 ; Vol. 117, No. 19. pp. 4468-4474.
@article{dbee4acc1fb74b3b88b766d779f84218,
title = "Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy",
abstract = "BACKGROUND: The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: The authors retrospectively reviewed 84 patients with SP who were diagnosed and treated at The University of Texas MD Anderson Cancer Center during 1988 to 2008. The impact of tumor anatomic site, tumor size, and the presence of serum and urinary paraprotein at diagnosis was assessed on local control, survival, and the risk of developing multiple myeloma (MM). RESULTS: Fifty-nine patients (70{\%}) had bone SP, and 25 patients (30{\%}) had extramedullary SP. Serum paraprotein was present in 39 patients (46{\%}). The median radiation dose was 45 grays (Gy) (range, 36-53.4 Gy). Local control was achieved in 77 patients (92{\%}). Neither radiation dose nor tumor size predicted local control. The 5-year rate of progression to MM was 47{\%} and was higher for patients with bone SP (56{\%} vs 30{\%} for extramedullary SP; P =.021), and patients who had serum paraprotein detected at diagnosis (60{\%} vs 39{\%}; P =.016). On univariate analysis, patients aged <60 years and men had higher rates of progression to MM, although the differences were not significant (P =.048 and P =.29, respectively). Multivariate analysis revealed that bone location and serum protein at diagnosis were associated statistically with progression to MM. The 5-year overall survival rate for the entire patient cohort was 78{\%}, and no difference was observed between patients who had bone SP versus extramedullary SP (76{\%} vs 85{\%}, respectively; P =.274). CONCLUSIONS: The current results indicated that definitive radiation therapy for SP can provide excellent local control. Progression to MM remains the main problem and is more common among patients with bone SP and those who have serum paraprotein detected at diagnosis.",
keywords = "Bence-Jones, multiple myeloma, paraprotein, plasmacytoma, radiation",
author = "Valerie Reed and Jatin Shah and Medeiros, {L. Jeffery} and Ha, {Chul S} and Ali Mazloom and Weber, {Donna M.} and Arzu, {Isidora Y.} and Orlowski, {Robert Z.} and Thomas, {Sheeba K.} and Ferial Shihadeh and Raymond Alexanian and Dabaja, {Bouthaina S.}",
year = "2011",
month = "10",
day = "1",
doi = "10.1002/cncr.26031",
language = "English (US)",
volume = "117",
pages = "4468--4474",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Solitary plasmacytomas

T2 - Outcome and prognostic factors after definitive radiation therapy

AU - Reed, Valerie

AU - Shah, Jatin

AU - Medeiros, L. Jeffery

AU - Ha, Chul S

AU - Mazloom, Ali

AU - Weber, Donna M.

AU - Arzu, Isidora Y.

AU - Orlowski, Robert Z.

AU - Thomas, Sheeba K.

AU - Shihadeh, Ferial

AU - Alexanian, Raymond

AU - Dabaja, Bouthaina S.

PY - 2011/10/1

Y1 - 2011/10/1

N2 - BACKGROUND: The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: The authors retrospectively reviewed 84 patients with SP who were diagnosed and treated at The University of Texas MD Anderson Cancer Center during 1988 to 2008. The impact of tumor anatomic site, tumor size, and the presence of serum and urinary paraprotein at diagnosis was assessed on local control, survival, and the risk of developing multiple myeloma (MM). RESULTS: Fifty-nine patients (70%) had bone SP, and 25 patients (30%) had extramedullary SP. Serum paraprotein was present in 39 patients (46%). The median radiation dose was 45 grays (Gy) (range, 36-53.4 Gy). Local control was achieved in 77 patients (92%). Neither radiation dose nor tumor size predicted local control. The 5-year rate of progression to MM was 47% and was higher for patients with bone SP (56% vs 30% for extramedullary SP; P =.021), and patients who had serum paraprotein detected at diagnosis (60% vs 39%; P =.016). On univariate analysis, patients aged <60 years and men had higher rates of progression to MM, although the differences were not significant (P =.048 and P =.29, respectively). Multivariate analysis revealed that bone location and serum protein at diagnosis were associated statistically with progression to MM. The 5-year overall survival rate for the entire patient cohort was 78%, and no difference was observed between patients who had bone SP versus extramedullary SP (76% vs 85%, respectively; P =.274). CONCLUSIONS: The current results indicated that definitive radiation therapy for SP can provide excellent local control. Progression to MM remains the main problem and is more common among patients with bone SP and those who have serum paraprotein detected at diagnosis.

AB - BACKGROUND: The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy. METHODS: The authors retrospectively reviewed 84 patients with SP who were diagnosed and treated at The University of Texas MD Anderson Cancer Center during 1988 to 2008. The impact of tumor anatomic site, tumor size, and the presence of serum and urinary paraprotein at diagnosis was assessed on local control, survival, and the risk of developing multiple myeloma (MM). RESULTS: Fifty-nine patients (70%) had bone SP, and 25 patients (30%) had extramedullary SP. Serum paraprotein was present in 39 patients (46%). The median radiation dose was 45 grays (Gy) (range, 36-53.4 Gy). Local control was achieved in 77 patients (92%). Neither radiation dose nor tumor size predicted local control. The 5-year rate of progression to MM was 47% and was higher for patients with bone SP (56% vs 30% for extramedullary SP; P =.021), and patients who had serum paraprotein detected at diagnosis (60% vs 39%; P =.016). On univariate analysis, patients aged <60 years and men had higher rates of progression to MM, although the differences were not significant (P =.048 and P =.29, respectively). Multivariate analysis revealed that bone location and serum protein at diagnosis were associated statistically with progression to MM. The 5-year overall survival rate for the entire patient cohort was 78%, and no difference was observed between patients who had bone SP versus extramedullary SP (76% vs 85%, respectively; P =.274). CONCLUSIONS: The current results indicated that definitive radiation therapy for SP can provide excellent local control. Progression to MM remains the main problem and is more common among patients with bone SP and those who have serum paraprotein detected at diagnosis.

KW - Bence-Jones

KW - multiple myeloma

KW - paraprotein

KW - plasmacytoma

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=80051474225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051474225&partnerID=8YFLogxK

U2 - 10.1002/cncr.26031

DO - 10.1002/cncr.26031

M3 - Article

VL - 117

SP - 4468

EP - 4474

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -